Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases
Several clinical scenarios warrant discussion: You should consider speaking with your GP if: You have type 2 diabetes that is inadequately controlled despite lifestyle modifications and metformin therapy, and your HbA1c remains above target You are struggling with weight management despite optimised thyroid hormone replacement, and you might meet NICE criteria for medical weight management (typically requiring referral to specialist weight management services) You have cardiovascular disease alongside type 2 diabetes, as some GLP-1 agonists (semaglutide, liraglutide, dulaglutide) have demonstrated cardiovascular benefits Your current diabetes medications are causing problematic side effects or hypoglycaemia Before your appointment , it is helpful to: Ensure your thyroid function has been checked recently (within the past 6 months) Compile a list of all current medications, including levothyroxine dose and timing Document your weight history and any previous weight management attempts Note any family history of thyroid cancer or endocrine conditions Prepare questions about potential benefits, risks, and alternatives Your GP will assess your suitability for GLP-1 therapy by reviewing your medical history, current thyroid status, diabetes control (if applicable), and overall health
Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date
T2DM patients combined with MASLD appear to respond better to EX-BID or EX-QW compared to those without MASLD, resulting in greater benefits in terms of LFC and cardiometabolic improvement
10.1093/eurheartj/ehz425 34 NilssonM.BovK
